Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCT-I: Perioperative RC48 and Tislelizumab in High-Risk UTUC
NCT05912816Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, tislelizumab in upper tract urothelial carcinoma (UTUC), sponsored by Renji Hospital. Started Jun 2023; status: recruiting.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT05912816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912816.